Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma

ACTIVITY DESCRIPTION
Though treatment advances have improved outcomes for most patients, MM remains an incurable disease characterized by continuous relapse. However, the treatment landscape for relapsed/refractory MM (RRMM) has expanded in recent years, and patients who relapse and/or become refractory to initial therapies are benefiting from the increasing availability of a diverse range of novel agents, including B-cell maturation antigen (BCMA)"targeted immunotherapies. These agents hold promise for patients who have relapsed from or become refractory to previous therapies"but these additional options make navigating treatment significantly more challenging for clinicians. Furthermore, many current and emerging BCMA-targeted therapies are associated with unique adverse events that may be unfamiliar to clinicians.

In this virtual Q&A activity, experts provide evidence-based responses to challenging questions on incorporating new and emerging BCMA-targeted therapies that achieve durable remission for RRMM patients and minimizing the toxicities associated with their use. The activity includes animated videos demonstrating the mechanisms of action (MOAs) of several BCMA-targeted agents.

Educational Objectives
Upon completion of this activity, participants should be better able to:
• Distinguish between the efficacies, safety profiles, and MOAs of current and emerging BCMA-targeted agents for MM patients who have relapsed from or are resistant to multiple prior therapies
• Summarize the toxicity profiles of BCMA-targeted agents used to treat RRMM, particularly with respect to the immunotherapies most associated with cytokine release syndrome (CRS) and immune effector cell"associated neurotoxicity syndrome (ICANS)
• Optimize selection and sequencing of the most appropriate BCMA-targeted therapies for patients with RRMM